REDMILE

Abcuro develops therapies that target highly cytotoxic T cells for autoimmune diseases, including its lead candidate ulviprubart for inclusion body myositis.

BiotechHealthtechNewton, US

Steven A. Greenberg(Chief Scientific Advisor & Co-Founder)Steven A. Greenberg, MD(Chief Scientific Advisor & Co-Founder)John Alexander Martin(Executive Officer, Director)Stefano Gulla(Executive Officer)Evan Thompson(Executive Officer)David de Graaf(Executive Officer, Director)

Co-investorsBain Capital Life SciencesNew Enterprise Associates (NEA)RA CapitalSamsara BioCapitalSanofi VenturesMass General Brigham Ventures+8 more

Bambusa Therapeutics develops bispecific antibodies for immunological and inflammatory (I&I) disorders, using antibody engineering to target multiple I&I indications.

BiotechHealthtechMedical DevicesAustin, US

Shanshan Xu(Founder & Chief Executive Officer)inHelmut Jeggle(Co-Founder)Thang Ho(Chief Development Officer)Crystal MacKay(Chief Operating Officer)in

Co-investorsINCE CapitalRA CapitalBiotechnology Value FundJanus Henderson InvestorsSalvia

GRObio (GRO Biosciences) develops protein therapeutics using non-standard amino acids (NSAAs) via its GRO platform, aiming to improve protein potency, stability, and function.

BiotechDeep TechHealthtechCambridge, US

Daniel J Mandell(Executive Officer, Director)Tracey Lodie(Executive Officer)Christopher Gregg(Director)

BoardMing Fang(Director)Bruce Beutel(Director)Dan Becker(Director)

Co-investorsLeaps by BayerDigitalis VenturesDreamers VCRising TideAtlas VentureInnovation Endeavors+1 more

Home Biosciences was a venture builder in Continental Europe dedicated to creating and scaling biotech companies through an asset-centric, hub-and-spoke model, working with academics and scientists on drug discovery and molecular profiling projects.

AI & Machine LearningBiotechHealthtech

David Schilansky(Co-founder & Non-executive Chairman)inMagali Richard(Co-founder)in

Co-investorsSofinnova Partners

Lycia Therapeutics is a biotechnology company developing LYTAC (Lysosomal Targeting Chimera) therapeutics that bind disease-causing extracellular and cell-surface proteins and route them into the cell's lysosome for degradation.

BiotechHealthtechSouth San Francisco, US

Aetna Wun Trombley(President and CEO)Amy Bachrodt(Chief Financial Officer)Jeremy S. Caldwell(Executive Officer, Director)Chin Lee(Chief Medical Officer)Steve Staben(Chief Scientific Officer)Sofia Touami(Chief Business Officer)

Co-investorsVersant VenturesBAM ElevateFranklin TempletonHBM Healthcare InvestmentsInvusJanus Henderson Investors+4 more

Ambrosia Bio produces rare sugars such as Allulose as low- to no-calorie replacements for sugar, offering a similar taste, sweetness, and textural profile without artificial aftertaste.

BiotechFoodTech

Co-investorsAnimoca BrandsBrinc

Clear Labs develops fully automated next-generation sequencing (NGS) platforms that process genomic data into insights for research and surveillance applications across infectious disease, food safety, and oncology.

BiotechData & InfrastructureDeep TechHealthtechMedical DevicesSan Carlos, US

Sasan Amini(Co-founder & CEO)Ramin Khaksar(Executive Officer)inEdward Fan(Executive Officer)inBrodie Flanders(Executive Officer, Director)Kazutaka Ohno(Executive Officer)Farzad Naimi(Executive Officer, Director)

Co-investorsMenlo VenturesKhosla VenturesNimble VenturesDentsu VenturesFelicis VenturesNimble Partners+5 more

Climb is a French wealth management service that combines advisors with technology to grow clients' assets through an open-architecture selection of investment products (life insurance, retirement PER, real estate, private equity, tax-reduction schemes, crypto).

FintechSaaS

Aldric Emié(CEO)

Co-investorsKima VenturesAlly Bridge GroupRA Capital

DealForma is a curated biopharma deals database offering licensing deal comps, M&A data, company and drug pipeline profiles, funding rounds, and Tableau-based interactive dashboards with natural-language search.

BiotechData & InfrastructureHealthtech

Co-investorsTinySeedAlgerRA CapitalRTW Investments L.P.Sofinnova Ventures

Evox Therapeutics develops exosome-based gene editing therapies using its ExoEdit platform, which combines exosome delivery with a proprietary CRISPR-based editor to treat severe neurodegenerative and other genetically-driven diseases.

BiotechDeep Tech

Co-investorsOrbiMedOxford Science EnterprisesPanacea VentureCowen Healthcare InvestmentsGV (Google Ventures)

Genalyte is developing Merlin, an automated diagnostic device that processes blood samples on-site and returns lab results within minutes while the patient waits.

Digital HealthHardwareMedical Devices

Co-investorsBioBritBoutique Venture PartnersClaremont Creek VenturesFusionX VenturesIPD CapitalSamsara BioCapital+3 more

BiotechEmeryville, US

Andrew Allen(Executive Officer, Director)Vassiliki Economides(Executive Officer)Matthew Hawryluk(Executive Officer)Shefali Agarwal(Director)Elaine Jones(Director)Naiyer A. Rizvi(Director)

Co-investorsFrazier Life SciencesSofinnova Ventures

Provides pharmaceutical R&D services via the Cyto-Mine machine for single-cell analysis and characterisation.

Co-investors24 HaymarketQVenturesProvidence Investment Company LimitedSofinnova Partners

Star Therapeutics develops treatments aimed at addressing real-world patient needs.

BiotechSouth San Francisco, US

Adam Rosenthal(Founder & CEO)Jason Hafler(Director)Nancy Stagliano(Director)Michelle Carpenter(Executive Officer)Matthew Fust(Director)Amrit Nagpal(Director)

Co-investorsFrazier Life SciencesOrbiMedRA CapitalSanofi VenturesSofinnova VenturesAgent Capital+8 more

Syros Pharmaceuticals is a Massachusetts gene-control biotech developing small molecules that regulate disease gene expression.

Co-investorsAisling CapitalARCH Venture PartnersQuan CapitalFlagship Ventures